Impact of 2018 EU Risk Minimisation Measures and Revised Pregnancy Prevention Programme on Utilisation and Prescribing Trends of Medicinal Products Containing Valproate: An Interrupted Time Series Study
-
Published:2023-06-09
Issue:7
Volume:46
Page:689-702
-
ISSN:0114-5916
-
Container-title:Drug Safety
-
language:en
-
Short-container-title:Drug Saf
Author:
Abtahi ShahabORCID, Pajouheshnia Romin, Durán Carlos E., Riera-Arnau Judit, Gamba Magdalena, Alsina Ema, Hoxhaj Vjola, Andersen Morten, Bartolini Claudia, Kristiansen Sarah Brøgger, Brown Jeremy, Hallgreen Christine Erikstrup, Garcia-Poza Patricia, Gardarsdottir Helga, Gini Rosa, Girardi Anna, Holthuis Emily, Huerta Consuelo, Ibánez Luisa, Limoncella Giorgio, Martín-Pérez Mar, Paoletti Olga, Roberto Giuseppe, Souverein Patrick, Swart Karin M. A., Wing Kevin, Sturkenboom Miriam, Klungel Olaf
Funder
European Medicines Agency
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Toxicology
Reference34 articles.
1. Schachter SC, Garcia P, Dashe JF. Antiseizure medications: Mechanism of action, pharmacology, and adverse effects. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2021. 2. Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016;11(11): CD010224. 3. Wieck A, Jones S. Dangers of valproate in pregnancy. BMJ. 2018;18(361): k1609. 4. Reynolds EH, Green R. Valproate and folate: congenital and developmental risks. Epilepsy Behav. 2020;108: 107068. 5. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol. 2018;17(6):530–8.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|